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Friedreich’s Ataxia is a 
Neurodegenerative disease
Friedreich’s	ataxia	(FRDA)	
is an autosomal recessive 
neurodegenerative disorder. The 
progressive neurodegeneration, 
mostly affecting spinocerebellar 
regions,	is	due	to	a	deficiency	of	the	
protein frataxin.1	Affected	individuals	
suffer from gait disturbances, loss 
of hand coordination, dysarthria, 
loss of sensation and loss of muscle 
power.	Diabetes	and	hypertrophic	
cardiomyopathy also occur.
Generally,	onset	occurs	before	
the age of 25 years, but in atypical 
cases, onset may be delayed or even 
occur in childhood.1	Normally,	within	
15-20	years,	the	patient	becomes	
wheel-chair	bound,	and	ultimately,	
is	totally	incapacitated.	Affected	
individuals normally succumb from heart 
complications.
FRDA	is	the	most	common	inherited	
ataxia	in	Europe	and	its	prevalence	is	~	1	
in	30,000.2
Frataxin
Frataxin is the mitochondrial protein 
which	is	deficient	in	FRDA.	Controversy	
still	surrounds	its	function.	However,	
frataxin is believed to be involved in 
iron homeostasis inside the cell, acting 
as an iron chaperone and promoting 
the	biogenesis	of	haem	and	iron-sulfur	
clusters (ISCs) inside the mitochondria.3 
ISCs act as prosthetic groups for 
several enzymes and molecules,4 
including some that are used inside 
the mitochondria itself. Thus, frataxin 
deficiency	results	in	cellular	deficiency	
of	these	iron-containing	enzymes	and	
proteins, mitochondrial dysfunction 
(decreased Mitochondrial Respiratory 
Complex I, II and III function) and 
oxidative damage,5 destining the cell to 
death.
The Genetic Mutation in fRdA
FRDA	is	caused	by	a	GAA	repeat	
hyper-expansion	mutation	within	the	
first	intron	of	the	FXN	gene	that	codes	
for frataxin. The cytogenetic location 
of	the	frataxin	gene	is	9q13-q21.1.	The	
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difference between normal and affected 
individuals lies in the number of the 
GAA	repeat	sequences;	normal	alleles	
contain	less	than	30	triplets	whereas	
affected	alleles	have	from	~	60	to	more	
than	1000	GAA	triplets	(Figure	1).
The Epigenetic Mechanisms 
Responsible in fRdA
Mounting research is showing that 
the molecular mechanism could be 
an epigenetic silencing of the mutated 
FXN	gene.	The	chromatin	in	which	
the gene lies undergoes epigenetic 
heterochromatisation, i.e. epigenetic 
mechanisms cause the chromatin 
to assume a condensed structure 
and hence it cannot be transcribed 
because the transcription machinery 
is	prohibited	access	to	the	DNA	
sequence.	Characteristically,	the	
heterochromatisation is brought about 
by classic epigenetic mechanisms, 
notably dNA methylation and 
nucleosomal histone modifications. 
But other epigenetic molecular 
players may also have a role, e.g. 
heterochromatin-protein 1 (hP-1), 
CTCf (CCCTC-binding factor) and 
fAST-1 (FXN Antisense Transcript-1). 
The epigenetic aberrations (also called 
epimutations) that are commonly found 
in	FRDA	are	hypoacetylation of the 
nucleosomal core histones H3 and 
H4 and tri-methylation of the amino 
acid Lysine in position 9 of histone 
h3 (h3 lys9m3). These epimutations 
involving	histones,	together	with	DNA	
hypermethylation, are very typical 
of	heterochromatin-mediated	gene	
silencing that have also been found in 
other medical conditions, like cancer 
(here mostly localised to promoters of 
tumour suppressor genes).
Epigenetic-Based Treatment as a 
Potential Strategy to Treat fRdA
Definitely,	the	FXN	gene	is	an	excellent	
target for epigenetic modulation 
therapy6 for three valid reasons. First, 
the most common type of mutation 
(affecting	both	alleles)	is	present	in	98%	
of	individuals	affected	by	FRDA.	Thus,	
targeting	the	epimutated	FXN	gene	is	
very rational. Secondly, the mutation 
affects	the	first	intron	of	the	FXN	gene.	
Thus, if the epigenetic aberrations are 
lifted through epigenetic modulation 
intervention,	it	would	leave	the	FXN	
coding	DNA	sequence	unaffected;	
transcription followed by splicing would 
occur and a functioning frataxin protein 
would be synthesised. Lastly, the 
heterozygous carriers show no obvious 
symptoms	even	though	they	have	~	
50%	deficiency	of	frataxin.	This	implies	
that	a	good	epigenetic-based	treatment	
only needs to increase the frataxin level 
to modestly approximate that found in 
carriers.
To address the epigenetic 
modulation	targeting	of	the	FXN	gene,	
several in vitro and in vivo models 
have been devised. These models, 
besides serving to study the molecular 
epigenetic hallmarks associated with 
the	mutated	FXN	gene	(see	above),	
are also being used in the search of 
new	epigenetic-based	treatments	
for the disease. Forexample, Soragni 
et al.6 created a molecular model of 
FRDA	that	could	be	used	to	carry	out	
high-throughput	analyses	of	potential	
substances. They also showed that 
the	GAA*TTC-induced	transcriptional	
silencing in their model could be 
somewhat alleviated by compounds 
that have already been shown to 
stimulate	FXN	expression	in	human	cell	
lines.
Herman	et al.7 managed to 
synthesise a class of histone 
deacetylase inhibitors (hDAcIs) 
that	reversed	FXN	silencing	in	
lymphoblastoid cells and in primary 
non-replicating	lymphocytes	from	
individuals	with	FRDA.	These	HDACIs	
increased the level of frataxin to 
those of carriers, and no toxicity was 
observed.	The	HDACIs	directly	affected	
the	histones	associated	with	FXN	and	
increased acetylation at particular 
lysine	residues.	This	class	of	HDACIs	
were	analogous	to	the	compound	BML-
210.	Amongst	them,	the	highly	active	
compound	was	4b.	A	follow-up	paper	
by Rai et al.8, with almost the same 
researchers	as	in	the	paper	by	Herman	
et al.7, made a further step to assess 
these compounds as potential drugs 
figure 1.  If	the	FXN	gene	contains	fewer	than	12	GAA	repeats,	it	is	referred	to	as	short	normal.	If	
the	GAA	segment	is	repeated	12	to	30	times,	it	is	referred	to	as	long	normal.	Mutant	alleles	often	
contain	from	60	to	even	1800	GAA	repeats
...the use of such drugs is confirming 
that epigenetic modulation can be 
a feasible treatment option, not only 
for cancer, but also for a growing 
list of diseases where epigenetic 
mechanisms of gene expression 
underline their pathogenesis
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to	treat	FRDA.	They	investigated	
their	efficacy	and	acute	toxicity	
in	an	FRDA	mouse	model	(KIKI	
mouse). One compound was very 
promising.	This	was	compound	106,	
a	derivative	of	4b.	This	investigation	
is	just	an	early	attempt	of	epigenetic-
based	treatment	for	FRDA.	It	
looks promising but the effect of 
increased histone acetylation was 
only	evident	in	the	brain	for	24	
hours after the last injection and 
had completely disappeared after a 
week.	The	KIKI	mice	just	received	
three subcutaneous doses of 
compound	106,	i.e.	once	a	day	for	
three consecutive days. From this 
investigation it is clear that further 
research is needed to see what 
the correct doses are, in order to 
maintain the histone modulation 
continually, without collateral 
effects (like toxicity) with long term 
treatments.
Even	though,	Soragni	et al.6 
proposed that their cell line could be 
adopted	for	high-throughput	analyses	
in the search for new therapeutics for 
FRDA,	they	knew	that	an	appropriate	
cellular model should not differ 
greatly from the cell types primarily 
affected	in	FRDA,	i.e.	neurons	and	
heart	cells.	It	was	not	long	that	Ku	
and Soragni et al.9 found the answer 
in	FRDA	iPS	(induced	pluripotent	
stem) cells. They reprogrammed 
fibroblasts	into	induced	pluripotent	
stem cells which were then 
differentiated into neurons. They 
then	demonstrated	that	the	FRDA	
neuronal	cells	responded	to	HDACIs.	
In	2011,	permission	was	given	to	
Repligen Corporation of Waltham, 
US,	for	pre-clinical	investigation	of	
candidate	(RG2833),	and	Phase	I	
safety trials in human subjects are 
on their way.10	HDACIs	are	surely	
showing superiority. But epigenetic 
modulation can also be made 
through other molecular players. 
Indeed, translational therapeutic 
research should also be done with 
histone methylation reducing drugs 
(e.g.	splitomicin),	DNA	methylation	
inhibitors (e.g. zebularine) and 
GAA-interacting	compounds	(e.g.	
pentamidine	and	DB221).
Conclusion
Epigenetic-based	treatment	
strategies	are	rational	and	the	first	
generation	of	epigenetic-based	
drugs has already been approved 
by	FDA,	e.g.	for	myelodysplastic	
syndrome. Indeed, the use of such 
drugs	is	confirming	that	epigenetic	
modulation can be a feasible 
treatment option, not only for cancer, 
but also for a growing list of diseases 
where epigenetic mechanisms of 
gene expression underline their 
pathogenesis.11 Since epigenetic 
changes are potentially reversible 
and are thought to be responsible 
for a wide range of diseases, the 
scope of epigenetic therapy is likely 
to expand.12	And	FRDA	is	surely	next	
in line.  
figure 2.	Putative	silencing	pathway	in	FRDA.	On	the	far	left,	is	an	active	FXN gene. Its chromatin 
organization	consists	of	its	DNA	sequence	(green)	wound	around	nucleosomes	(grey	beads),	
consisting	of	octomers	of	the	protein	histone.	The	histones	have	amino-acid	tails	that	protrude	
out	from	the	nucleosomes	and	when	they	are	acetylated	(Ac,	acetyl),	an	open	chromatin	template	
forms	and	transcription	of	FXN	is	possible.	Above	normal	GAA	repeats	push	the	pathway	to	the	
right	towards	heterochromatin	formation.	An	early	step	in	the	process	of	heterochromatization	
is	deacetylation	of	the	lysines	on	the	histones	by	HDAC	(histone	deactylases).	Then	HMTases	
(histone	methyltransferases)	methylates	histone	H3	tail	on	its	Lys9.	This	facilitates	HP1	(purple)	to	
bind	and	as		nucleosomes	come	closer,	HP1	dimers	form,	producing	a	condensed	higher-order	
heterochromatin	structure.	This	heterochromatization	does	not	allow	transcription	of	the	FXN	
gene. Adapted from ‘Breaking the silence in Friedreich’s ataxia’ by Richard Festenstein.
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